Edition:
United States

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

34.20EUR
17 Aug 2018
Change (% chg)

€0.65 (+1.94%)
Prev Close
€33.55
Open
€33.90
Day's High
€34.40
Day's Low
€33.60
Volume
33,614
Avg. Vol
117,331
52-wk High
€39.35
52-wk Low
€8.90

Chart for

About

Mithra Pharmaceuticals SA is a Belgium-based company that provides pharmaceutical services. It was founded in 1999.

Overall

Beta: --
Market Cap(Mil.): €1,287.27
Shares Outstanding(Mil.): 37.64
Dividend: --
Yield (%): --

Financials

  MITRA.BR Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -1.02 -- --
ROI: -19.68 12.92 12.63
ROE: -36.91 14.94 14.82

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

May 03 2018

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

Apr 19 2018

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

Apr 12 2018

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

Mar 28 2018

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* ‍MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA​

Mar 20 2018

BRIEF-Mithra And Alvogen Sign LSA For Vaginal Contraception Ring In Russia

* MITHRA AND ALVOGEN SIGN LSA FOR VAGINAL CONTRACEPTION RING IN RUSSIA

Mar 16 2018

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

Mar 08 2018

Earnings vs. Estimates